However, the company reports strong underlying growth in other regions, led by mid-teens growth in the Americas and South East Asia. £23m of funding headroom gives the company plenty of scope to continue its strong R&D program, diversifying away from dependence on Aivlosin sales in China. Revenue and margin estimates for FY23/24E have been revised as a result of ongoing weakness in the Chinese market and the impact of the sales tax issue revealed earlier this month. However, we continue to see s ....

31 Aug 2022
ROW growth offset by volatility in China

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ROW growth offset by volatility in China
ECO Animal Health Group plc (EAH:LON) | 104 -0.5 (-0.5%) | Mkt Cap: 70.4m
- Published:
31 Aug 2022 -
Author:
Chris Glasper -
Pages:
3 -
However, the company reports strong underlying growth in other regions, led by mid-teens growth in the Americas and South East Asia. £23m of funding headroom gives the company plenty of scope to continue its strong R&D program, diversifying away from dependence on Aivlosin sales in China. Revenue and margin estimates for FY23/24E have been revised as a result of ongoing weakness in the Chinese market and the impact of the sales tax issue revealed earlier this month. However, we continue to see s ....